ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.40bn
- $2.44bn
- $1.07bn
Brief: Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome
Acadia Pharmaceuticals appoints Catherine Owen Adams CEO, shares fall
Brief: Catherine Owen Adams Succeeds Steve Davis As CEO Of Acadia Pharmaceuticals
Brief: Axcelead Drug Discovery Partners Enters Into Master Service Agreement For Drug Discovery Projects With Acadia Pharmaceuticals
U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18
Acadia Pharmaceuticals Inc Expected To Post Earnings Of 18 Cents A Share: Earnings Preview
Brief: ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP- Corpay, Epam Systems, MKS Instruments
U.S. RESEARCH ROUNDUP- Crescent Energy, Rockwell Automation, Transdigm Group
Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee
Brief: Acadia Pharmaceuticals Q1 EPS USD 0.1 Vs. IBES Estimate USD 0.05
Acadia Pharmaceuticals Inc Expected To Post Earnings Of 5 Cents A Share: Earnings Preview
Brief: Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada
U.S. RESEARCH ROUNDUP-Apollo, Tesla, UDR
U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Kinetik Holdings, Motorola Solutions
U.S. STOCKS ON THE MOVE-Rumble, Geron, Gold miners